Literature DB >> 16723591

Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.

George G Zhanel1, Matthew Mayer, Nancy Laing, Heather J Adam.   

Abstract

The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa. Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723591      PMCID： PMC1479108          DOI： 10.1128/AAC.01620-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  The mutant selection window and antimicrobial resistance.

Authors:  Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 2.  Quinolones in 2005: an update.

Authors:  F Van Bambeke; J-M Michot; J Van Eldere; P M Tulkens
Journal:  Clin Microbiol Infect       Date:  2005-04       Impact factor: 8.067

Review 3.  A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.

Authors:  Jeffrey D Fuller; Donald E Low
Journal:  Clin Infect Dis       Date:  2005-05-26       Impact factor: 9.079

Review 4.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

5.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

Authors:  George G Zhanel; Tamiko L Hisanaga; Nancy M Laing; Melanie R DeCorby; Kim A Nichol; Lorraine P Palatnik; Jack Johnson; Ayman Noreddin; Godfrey K M Harding; Lindsay E Nicolle; Daryl J Hoban
Journal:  Int J Antimicrob Agents       Date:  2005-11       Impact factor: 5.283

7.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.

Authors:  Nasia Safdar; Jo Handelsman; Dennis G Maki
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

9.  Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Yu Lubenko; Yury A Portnoy; Stephen H Zinner
Journal:  Int J Antimicrob Agents       Date:  2004-05       Impact factor: 5.283
  9 in total
  9 in total

1.  A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.

Authors:  Kathy K Wang; Laura K Stone; Tami D Lieberman; Michal Shavit; Timor Baasov; Roy Kishony
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

2.  Effect of Ciprofloxacin, Levofloxacin, and Ofloxacin on Pseudomonas aeruginosa: A case control study with time kill curve analysis.

Authors:  Tiar Sondang Uli Sihotang; Agung Dwi Wahyu Widodo; Pepy Dwi Endraswari
Journal:  Ann Med Surg (Lond)       Date:  2022-09-16

Review 3.  Drug interactions and the evolution of antibiotic resistance.

Authors:  Pamela J Yeh; Matthew J Hegreness; Aviva Presser Aiden; Roy Kishony
Journal:  Nat Rev Microbiol       Date:  2009-06       Impact factor: 60.633

4.  Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae.

Authors:  Wentao Ni; Chuanqi Wei; Chufei Zhou; Jin Zhao; Beibei Liang; Junchang Cui; Rui Wang; Youning Liu
Journal:  Front Microbiol       Date:  2016-08-19       Impact factor: 5.640

Review 5.  Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives.

Authors:  Mohamed Rhouma; Francis Beaudry; William Thériault; Ann Letellier
Journal:  Front Microbiol       Date:  2016-11-11       Impact factor: 5.640

6.  Antibacterial Loaded Spray Dried Chitosan Polyelectrolyte Complexes as Dry Powder Aerosol for the Treatment of Lung Infections.

Authors:  Brahmeshwar Mishra; Madhusmita Mishra; Sarita Kumari Yadav
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

7.  Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs.

Authors:  Chongshan Dai; Tingting Zhao; Xing Yang; Xilong Xiao; Tony Velkov; Shusheng Tang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

8.  Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance.

Authors:  Xuejie Xu; Li Xu; Ganjun Yuan; Yimin Wang; Yunqiu Qu; Meijing Zhou
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

Review 9.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.